In focus
Latest feed
Boehringer Ingelheim’s Survodutide Shows Promise in Late‑Stage Obesity Trials
Eli Lilly’s Next‑Gen Obesity Pill Shows Promise in Tackling Sleep Apnea and More
Eli Lilly’s Next‑Gen Obesity Pill Shows Promise for Sleep Apnea and More
Pfizer's Bold Gambit: A Nearly Half-Billion Dollar Bet on China's Obesity Market
